INOVIO to Participate in Upcoming Scientific and Investor Conferences

Core Viewpoint - INOVIO is actively participating in several upcoming scientific and investor conferences to showcase its advancements in DNA medicines aimed at treating HPV-associated diseases, cancer, and infectious diseases [1] Conference Participation - INOVIO will present at the American Association for Cancer Research Immuno-Oncology Conference on February 18, focusing on the treatment of Recurrent Respiratory Papillomatosis (RRP) with DNA immunotherapy INO-3107 [1] - The company will also participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, featuring a fireside chat webcast [1] - At the Festival of Biologics on March 4, INOVIO will present findings on the safety and pharmacokinetics of SARS-CoV-2 DNA-Encoded Monoclonal Antibodies in a Phase 1 trial [1] - The Citizens Life Sciences Conference on March 10 will include another fireside chat with INOVIO's management team [1] Company Overview - INOVIO is a biotechnology company dedicated to developing and commercializing DNA medicines that empower the body to produce its own disease-fighting tools [1]